/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

K

Karl D. Lewis

Regeneron (United States)(US)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

349

Papers

28.1K

Citations

62

h-index

145

i10-index

Karl D. Lewis is an academic researcher from Regeneron (United States). The author has contributed to research in topics: Cancer Immunotherapy and Biomarkers & Melanoma and MAPK Pathways & CAR-T cell therapy research. The author has an h-index of 62, co-authored 297 publications.

ORCID: 0000-0001-9893-0537

Research Topics

Cancer Immunotherapy and Biomarkers Melanoma and MAPK Pathways CAR-T cell therapy research Immunotherapy and Immune Responses Cutaneous Melanoma Detection and Management

Papers by this author

works

Efficacy and Safety of Vismodegib in Advanced Basal-Cell Carcinoma

2012 · New England Journal of Medicine · 1,419 citations

https://doi.org/10.1056/nejmoa1113713

Aleksandar Sekulić Michael R. Migden Anthony E. Oro Luc Dirix

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial

2015 · The Lancet Oncology · 423 citations

https://doi.org/10.1016/s1470-2045(15)70100-2

Michael R. Migden Alexander Guminski Ralf Gutzmer Luc Dirix

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

2021 · Journal of Clinical Oncology · 382 citations

https://doi.org/10.1200/jco.21.00612

Amod A. Sarnaik Omid Hamid Nikhil I. Khushalani Karl D. Lewis

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

2022 · Journal for ImmunoTherapy of Cancer · 285 citations

https://doi.org/10.1136/jitc-2022-005755

Jason Chesney Karl D. Lewis Harriet M. Kluger Omid Hamid

Basal Cell Skin Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology

2016 · Journal of the National Comprehensive Cancer Network · 272 citations

https://doi.org/10.6004/jnccn.2016.0065

Christopher K. Bichakjian Thomas Olencki Sumaira Z. Aasi Murad Alam

Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC

2015 · Journal of the American Academy of Dermatology · 207 citations

https://doi.org/10.1016/j.jaad.2015.03.021

Aleksandar Sekulić Michael R. Migden Karl D. Lewis John D. Hainsworth

Research topics

topics

Cancer Immunotherapy and Biomarkers

Melanoma and MAPK Pathways

CAR-T cell therapy research

Immunotherapy and Immune Responses

Cutaneous Melanoma Detection and Management

Chat about Author

Papers

Chat

Click to start Chat